Altimmune Stock Technical Analysis
| ALT Stock | USD 3.50 -0.10 -2.78% |
As of the 13th of March 2026, Altimmune is valued at 3.50 per share. Indicator levels currently stand at Risk Adjusted Performance of -0.04, mean deviation of 3.66, and Standard Deviation of 6.14. Historical price dispersion and volume trends are incorporated into the evaluation. Values are analyzed in relation to historical volatility thresholds.
Altimmune Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Altimmune, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to AltimmuneAltimmune | Build AI portfolio with Altimmune Stock |
Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 17.22 | Strong Buy | 9 | Odds |
Current and historical analyst recommendations for Altimmune are summarized from research sources. The summary includes average consensus context. Research analysts covering Altimmune use a range of valuation methodologies - including DCF, comparable company analysis, and sum-of-the-parts - to derive price targets for Altimmune. Divergences in these targets reflect differences in assumptions about growth, margins, and discount.
Understanding Altimmune includes distinguishing between market value and book value, where book value reflects Altimmune's accounting equity. Altimmune's market capitalization is 475.88 M. A P/B ratio of 2.12 indicates the market values Altimmune above its accounting book value. Enterprise value stands at 238.11 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Altimmune's value from its trading price, which are computed with different methods. For Altimmune, key inputs include a P/B ratio of 2.12, ROE of -50.57%, and revenue of 41 K. By contrast, market price reflects the level where buyers and sellers transact.
What if' Analysis
Running a what-if backtest on Altimmune gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Altimmune's historical reward profile was stable enough to support the current thesis.
| 12/13/2025 |
| 03/13/2026 |
An initial 0.00 allocation to Altimmune on December 13, 2025 held through today would generate 0.00 in cumulative gains. Overall, this is a 0.0% total return in Altimmune in aggregate over 90 days. Altimmune is often compared with DBV Technologies, Annexon, Frequency Therapeutics, EnGene Holdings, Larimar Therapeutics, Aura Biosciences, and Amarin PLC based on sector and business overlap. The comparison helps frame competitive context. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver dise... More
Altimmune Momentum Range Indicators Summary
This section highlights upside and downside signals that contextualize Altimmune price behavior. This view helps summarize momentum conditions without implying direction.
| Information Ratio | -0.05 | |||
| Maximum Drawdown | 34.32 | |||
| Value At Risk | -6.22 | |||
| Potential Upside | 9.6 |
Altimmune Volatility and Risk Indicators Summary
This section presents risk metrics that describe Altimmune's historical price variability. The measures summarize variability without implying direction.| Risk Adjusted Performance | -0.04 | |||
| Jensen Alpha | -0.32 | |||
| Total Risk Alpha | -0.02 | |||
| Treynor Ratio | -0.30 |
The mean reversion effect in Altimmune is stronger when the initial deviation was driven by sentiment rather than fundamental change. Identifying the root cause of Altimmune's price dislocation is essential before acting.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.04 | |||
| Market Risk Adjusted Performance | -0.29 | |||
| Mean Deviation | 3.66 | |||
| Coefficient Of Variation | -1,637 | |||
| Standard Deviation | 6.14 | |||
| Variance | 37.65 | |||
| Information Ratio | -0.05 | |||
| Jensen Alpha | -0.32 | |||
| Total Risk Alpha | -0.02 | |||
| Treynor Ratio | -0.30 | |||
| Maximum Drawdown | 34.32 | |||
| Value At Risk | -6.22 | |||
| Potential Upside | 9.6 | |||
| Skewness | -0.51 | |||
| Kurtosis | 4.39 |
Altimmune Backtested Returns
Altimmune demonstrates a relatively elevated risk exposure under current market conditions. It maintains a Sharpe Ratio of -0.0742, illustrating dispersion-adjusted losses. We identified twenty-three technical indicators influencing the company's volatility profile. Please assess metrics such as mean deviation of 3.66, standard deviation of 6.14, and risk-adjusted performance of -0.04 to confirm statistical stability. The firm maintains a market beta of 1.28, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Altimmune will likely underperform. At this point, Altimmune has a negative expected return of -0.47%. Please make sure to verify Altimmune's relationship between the Kurtosis and day typical price, to decide if Altimmune's performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.21 |
Weak reverse predictability
Altimmune exhibits weak reverse predictability. Autocorrelation measures the degree of predictability between Altimmune time series from 13th of December 2025 to 27th of January 2026 and from 27th of January 2026 to 13th of March 2026. Persistent correlation between intervals suggests underlying momentum patterns in Altimmune that may carry forward. The measured coefficient of -0.21 means over 21.0% of Altimmune's recent price variance traces back to prior period behavior. Given that Altimmune has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.21 | |
| Spearman Rank Test | -0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.33 |
Technical analysis for Altimmune examines price and volume behavior across market regimes. The view references moving averages, RSI, regressions, and chart pattern signals.
Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Altimmune volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of Altimmune evaluates price structure, momentum, and volatility clustering. Range expansion increases sensitivity to execution and spread conditions. Altimmune has a market cap of 475.88 M, ROE of -50.57%.
Unless otherwise specified, data for Altimmune is compiled from periodic company reporting and market reference feeds and standardized for comparability. Analyst inputs may be included when coverage is available. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardAltimmune Technical Indicators
A technical review of Altimmune can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.04 | |||
| Market Risk Adjusted Performance | -0.29 | |||
| Mean Deviation | 3.66 | |||
| Coefficient Of Variation | -1,637 | |||
| Standard Deviation | 6.14 | |||
| Variance | 37.65 | |||
| Information Ratio | -0.05 | |||
| Jensen Alpha | -0.32 | |||
| Total Risk Alpha | -0.02 | |||
| Treynor Ratio | -0.30 | |||
| Maximum Drawdown | 34.32 | |||
| Value At Risk | -6.22 | |||
| Potential Upside | 9.6 | |||
| Skewness | -0.51 | |||
| Kurtosis | 4.39 |
March 13, 2026 Daily Trend Indicators
A technical review of Altimmune can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Accumulation Distribution | 176,037 | ||
| Daily Balance Of Power | -0.48 | ||
| Rate Of Daily Change | 0.97 | ||
| Day Median Price | 3.58 | ||
| Day Typical Price | 3.55 | ||
| Price Action Indicator | -0.13 |
Additional Tools for Altimmune Stock Analysis
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |